Patient Case Study: Stage IV Breast Cancer

Uncovering More at Progression

Northstar Response®-Informed Treatment Planning

‍

BACKGROUND

‍

RESULTS

‍

TAKEAWAY

Northstar results and clinical history suggests the development of acquired resistance mutations to aromatase inhibitor therapy, a common challenge in the treatment of HR-positive metastatic breast cancer. Comprehensive profiling at molecular progression revealed new treatable alterations found at very low VAF, highlighting the unprecedented sensitivity* of Northstar Select®. Progressive disease was confirmed by imaging one month after this insight was provided by Northstar Response®.

‍

‍